Contents
20 June 2018
Vol 10, Issue 446
Vol 10, Issue 446
Research Articles
- Afatinib restrains K-RAS–driven lung tumorigenesis
K-RAS–mutated lung adenocarcinomas depend on ERBB signaling, and pan-ERBB inhibitors impair K-RAS–driven lung tumorigenesis.
- The ERBB network facilitates KRAS-driven lung tumorigenesis
G12 mutant KRAS requires tonic ERBB network activity for initiation and maintenance of lung cancer.
- Tissue engineering toward temporomandibular joint disc regeneration
Tissue-engineered implants integrate with native tissue, are capable of adaptive remodeling, and improve healing of temporomandibular joint disc defects in minipigs.
- Interrogation of nonconserved human adipose lincRNAs identifies a regulatory role of linc-ADAL in adipocyte metabolism
Nonconserved linc-ADAL interacts with distinct cytoplasmic and nuclear factors to regulate human adipocyte differentiation and metabolism.
Editors' Choice
- A molecular warning system for invasive pneumococcus
A genome-wide association study of Streptococcus pneumoniae identifies and validates bacterial loci associated with invasive infection.
- Ketogenic bugs as epilepsy drugs
The gut microbiome mediates the beneficial effects of a ketogenic diet on epileptic seizures through modulation of GABA/glutamate ratios in the hippocampus.
- Improving “gut feelings” for poorly water-soluble drugs
A nanocarrier system self-assembled in the intestine significantly improves oral availability of poorly water-soluble drugs.
About The Cover
ONLINE COVER Breathing New Life into Kinase Inhibitors. Mutations in signaling pathways can allow lung cells to become cancerous, eventually leading to the formation of lung tumors like the one pictured here. KRAS mutations drive the growth of many lung cancers and typically have been thought to be resistant to EGFR tyrosine kinase inhibition. Two groups (Moll et al. and Kruspig et al.) have independently reassessed this notion using patient samples and mouse models. They uncovered the mechanisms responsible for KRAS-mutation resistance to kinase inhibition and show how combination treatment targeting EGFR and other kinases could effectively target this common subset of lung cancers. [CREDIT: MOREDUN ANIMAL HEALTH LTD/SCIENCE SOURCE]
